Helix Acquisition in a regulagtory filing said shareholders yesterday voted in favor of combining with Moonlake Immunotherapeutics AG, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases.
Helix said 8,080,845 shares were redeemed ahead of the vote, representing about 70% of the SPAC’s cash in trust.
As announced in October, Moonlake was due to receive the $115 million held in Helix Acquisition’s trust at that time, as well as a $115 million PIPE led by the SPAC’s sponsor Cormorant Asset Management, with participants including BVF Partners, 683 Capital Partners, Asymmetry Capital Management, funds managed by Ghost Tree Capital Group, Monashee Investment Management, RTW Investments, Surveyor Capital, TCG X and funds managed by Tekla Capital Management.
No word on when the deal will close, when Moonlake is expected to begin trading on the Nasdaq under the symbol MLTX. Read more.
